Clinical trial NCT02785250: Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
Official title: A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Recurrent Epithelial Ovarian Cancer
Recurrent Fallopian Tube Cancer
Recurrent Peritoneal Cancer
Keywords: T cell activation
immunotherapy
ovarian
fallopian tube
peritoneal
cancer
recurrent
tumor
measurable
Lead sponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.)
Sponsor class: INDUSTRY
Collaborators: name: Incyte Corporation
First posted: 2016-05-27
Enrollment: 85
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: T cell activating therapy DPX-Survivac, low dose oral cyclophosphamide, and IDO1 inhibitor epacadostat will be tested together for the first time in patients with recurrent ovarian, fallopian tube, or peritoneal cancer to determine the safety and potential immune-modulating activity of the combination of these agents.

Detailed description: The Phase 1b component is a multicenter, non-randomized, open label, uncontrolled, safety and effectiveness study to identify the recommended Phase 2 dose (R2PD) of epacadostat in combination with DPX-Survivac and cyclophosphamide.

The Phase 2 component was initially a multicenter, randomized, open-label study to evaluate the safety and effectiveness of DPX-Survivac + cyclophosphamide with or without the RP2D of epacadostat. The design of the study has been amended to a single arm study in which up to 16 evaluable subjects will be enrolled to received DPX-Survivac plus intermittent low dose cyclophosphamide (i.e. treatment arm 2).

Eligibility criteria: Key Inclusion Criteria:

* Histologically confirmed, stage IIc-IV epithelial ovarian, fallopian tube or peritoneal cancer
* Platinum-resistant or -sensitive subjects after completing first-line treatment (debulking surgery and adjuvant or neoadjuvant treatment with standard of care treatment such as carboplatin and paclitaxel). Subjects may have had any number of subsequent lines of chemotherapy.
* Must have evidence of progressive disease with either biochemical (i.e. rising CA-125) and/or radiologic progression
* Must have measurable disease by RECIST v1.1, a successful pre-treatment tumor biopsy, and be willing to undergo tumor biopsy during treatment
* Ambulatory with an ECOG 0-1
* Life expectancy ≥ 6 months
* Meet protocol-specified laboratory requirements

Key Exclusion Criteria:

* Eligible for otherwise curative treatment or undergoing concurrent therapy
* Prior receipt of survivin based vaccines or immune checkpoint inhibitors (e.g. anti-CTLA-4, anti-PD-1, anti-PD-L1, or any other antibody or drug specifically targeting T cell co-stimulation) or an IDO inhibitor
* Concurrent second malignancy other than non-melanoma skin cancer, cervical carcinoma in situ, or controlled bladder cancer
* Clinical ascites
* Any single lesion greater than or equal to 4 cm (per RECIST v1.1)
* Malignant bowel obstruction
* History of autoimmune disease requiring treatment within the last two years (except vitiligo or diabetes)
* Recent history of thyroiditis
* Presence of a serious acute infection or chronic infection
* Active central nervous system (CNS) or leptomeningeal metastasis (brain metastases)
* GI condition that might limit absorption of oral agents
* Other serious intercurrent chronic or acute illness, including myocardial infarction or cerebrovascular event within 6 months
* Ongoing treatment with steroid therapy or other immunosuppressive
* Receipt of monoamine oxidase inhibitors (MAOIs) or UGT1A9 inhibitors
* Receipt of live attenuated vaccines
* Acute or chronic skin and/or microvascular disorders
* Edema or lymphedema in the lower limbs \> grade 2

Primary outcomes:
measure: Safety as measured by adverse event reporting (CTCAE)
timeFrame: up to 13 months
measure: Objective Response Rate (Phase 2 only)
timeFrame: up to 13 months
Secondary outcomes:
measure: Objective Response Rate (for each treatment group)
timeFrame: up to 13 months
measure: Duration of Response
timeFrame: up to 13 months
measure: Cell mediated immunity as measured by the antigen specific response in peripheral blood
timeFrame: bimonthly for up to 13 months
measure: Evaluation of treatment-induced changes in tumor infiltrating lymphocytes
timeFrame: at 8 to 10 weeks
measure: Time to Progression
timeFrame: up to 13 months
measure: Overall Survival
timeFrame: up to 13 months
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Stanford University
state: California
city: Augusta
country: United States
facility: Georgia Cancer Center at Augusta University
state: Georgia
city: New York
country: United States
facility: Lenox Hill Hospital
state: New York
city: Portland
country: United States
facility: Oregon Health & Sciences University, Knight Cancer Institute
state: Oregon
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
city: Dallas
country: United States
facility: Mary Crowley Cancer Research Center
state: Texas
city: Calgary
country: Canada
facility: Tom Baker Cancer Centre
state: Alberta
city: Toronto
country: Canada
facility: Princess Margaret Hospital
state: Ontario
city: Montréal
country: Canada
facility: Centre Hospitalier de l'Université de Montréal (CHUM)
state: Quebec
Study officials:
References: